ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Shiqi MaoFei ZhouYiwei LiuShuo YangBin ChenJian XuFengying WuXuefei LiChao ZhaoWanying WangQian LiuXiaofei YuKeyi JiaChuchu ShaoCaicun ZhouGuanghui GaoShengxiang RenPublished in: Cancer immunology, immunotherapy : CII (2021)
ICI plus chemotherapy showed superior ORR, PFS and OS than ICI alone patients with previous treated advanced NSCLC. These findings warrant further investigation.